Join
Live feed
·
PRReleasevia Quantisnow
SCYNEXIS Inc. logo

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

ByQuantisnow·Wall Street's wire, on your screen.
SCYX· SCYNEXIS Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SCYX (SCYNEXIS Inc.) and more on Quantisnow.